Research: Firms’ strategic decisions affect evolution of activism and emergence of mobilization

Research: Firms’ strategic decisions affect evolution of activism and emergence of mobilization

3D cell culture scaffolds prove to be invaluable tool for myelination research As expected, when activists are successful in preventing the establishment of a nuclear plant, there is an upsurge in similar protests in neighboring communities. Such a victory showcases activism as a viable opportunity for social change and activists remain mobilized to push further towards more ambitious goals. This dynamic is exemplified by the very first episode of protest against a nuclear power plant at Bodega Bay, California. In 1964 plans for the plant were canceled and, partly due to this success, a nationwide movement opposing nuclear power was soon born. A protracted cycle of protest starting in 1976 could not, instead, prevent the construction of a nuclear power plant in Seabrook, New Hampshire, which was concluded in 1986. Despite their failure in achieving their goal, however, the Seabrook protests connected and inspired people around the country, establishing a dominant model of large-scale direct-action organization for groups championing different issues, including the AIDS activist group ACT UP. Firms decisions can be considered critical events in a protracted conflict that not only determine local mobilization outcomes, but can also have boundary spanning effects», says Prof. Perretti. Furthermore, the idea that mobilization is more effective at its very onset proves wrong: all the conflicts about new plants go on for years, if not decades and activism effectiveness doesn't tend to wane over time. Source: Bocconi University Journal reference: Piazza, A. & Perretti. F. (2019) Firm behavior and the evolution of activism: Strategic decisions and the emergence of protest in US communities. Strategic Management Journal. doi.



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More